Drug Profile
CVN 766
Alternative Names: CVN-766Latest Information Update: 16 Feb 2023
Price :
$50
*
At a glance
- Originator Cerevance
- Class Behavioural disorder therapies
- Mechanism of Action Orexin receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psychiatric disorders
Most Recent Events
- 09 Jan 2023 Cerevance plans a phase II trial for Schizophrenia in Q4 2023
- 09 Jan 2023 Adverse event and pharmacokinetics data from in Psychiatric disorders (In volunteers) released by Cerevance
- 09 Jan 2023 Pharmacodynamics data from a preclinical trial in Psychiatric disoreders released by Cerevance